ProCE Banner Activity


Key Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence

Text Module

Review this expert analysis by Ritu Salani, MD, MBA, and Eva Y. Pan, PharmD, BCOP, focusing on the most recent practice-changing evidence for patients with ovarian, endometrial, and cervical cancers.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Nurses: 1.25 Nursing contact hours

Released: May 13, 2022

Expiration: May 12, 2023

No longer available for credit.



Eva Y. Pan

Eva Y. Pan, PharmD, BCOP

Clinical Oncology Pharmacy Specialist
Yale-New Haven Hospital
New Haven, Connecticut

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from



Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with gynecologic cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess for appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancer
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination regimens
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings

  • Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Eva Y. Pan, PharmD, BCOP

Clinical Oncology Pharmacy Specialist
Yale-New Haven Hospital
New Haven, Connecticut

Eva Y. Pan, PharmD, BCOP, has no relevant conflicts of interest to report.

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA, has disclosed that she has received consulting fees from Arcus Biosciences, Genentech, GlaxoSmithKline, Instil Bio, Merck, and Seagen, and research support from Regeneron Pharmaceuticals.

Staff Disclosure


Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kay Orbaugh, MSN, NP, AOCNP, has received speaker fees from AstraZeneca, Bristol Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-138-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 13, 2022, through May 12, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with gynecologic malignancies.